Narlaprevir is a synthetic hepatitis C virus (HCV) NS3/4A serine protease inhibitor developed as a direct-acting antiviral compound. It is also known by the development code SCH 900518.
Narlaprevir targets the HCV NS3/4A protease, an enzyme required for processing the viral polyprotein into functional proteins necessary for viral replication. By inhibiting this protease, Narlaprevir interferes with the HCV replication cycle.
Narlaprevir has the molecular formula C36H61N5O7S, CAS Number 865466-24-6, and molecular weight approximately 707.97 g/mol. These chemical identity values are supported by PubChem and ChEMBL.
Narlaprevir is a well-characterized antiviral pharmaceutical API associated with direct-acting antiviral research and HCV NS3/4A protease inhibition.
Important API quality attributes include identity, assay, related substances, water content, residual solvents, elemental impurities and other applicable pharmaceutical quality parameters.
Narlaprevir is also identified as SCH 900518 / SCH-900518 in pharmaceutical and scientific literature.
CAS Number: 865466-24-6
Molecular Formula: C36H61N5O7S
Molecular Weight: 707.97 g/mol
Chemical Name: Narlaprevir
Development Code: SCH 900518
Drug Class: HCV NS3/4A Protease Inhibitor
Therapeutic Class: Direct-Acting Antiviral
Therapeutic Area: Infectious Diseases / Hepatology
Molecule Type: Synthetic Small Molecule
Narlaprevir is a reversible inhibitor of the HCV NS3/4A serine protease. The NS3/4A protease is essential for cleavage and processing of the HCV polyprotein.
Its antiviral mechanism includes:
The International Union of Basic and Clinical Pharmacology describes narlaprevir as an oral HCV NS3 serine protease inhibitor.
Narlaprevir API is relevant to:
Narlaprevir was developed as a direct-acting antiviral for chronic hepatitis C virus infection, particularly targeting HCV NS3/4A protease.
Clinical development and pharmacological studies investigated Narlaprevir in HCV treatment, including its use with other antiviral agents. Its regulatory and clinical status should be described according to the relevant country and current regulatory framework rather than implying universal approval.
The HCV NS3/4A protease is an essential viral enzyme involved in processing the HCV polyprotein.
Narlaprevir binds to the protease and inhibits its enzymatic activity. This prevents proper processing of viral proteins required for productive viral replication.
Research has also investigated the molecular basis of resistance to Narlaprevir-associated NS3 mutations.
Narlaprevir is generally described as a white to off-white solid/powder in chemical supplier and research-product information.
Its physical properties, crystalline characteristics, particle size and other material attributes should be controlled according to the applicable pharmaceutical/API specification.
A controlled Narlaprevir API manufacturing process may involve:
Typical Narlaprevir API testing may include:
Store Narlaprevir API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive moisture, heat and direct light.
Final storage conditions should be established according to validated stability data, the applicable API specification and the manufacturer's SDS.
Narlaprevir is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |